Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPZM NASDAQ:IRWD NASDAQ:PCRX NASDAQ:PRNB NYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsIRWDIronwood Pharmaceuticals$1.48-6.6%$1.26$0.53▼$5.13$257.46M0.31.39 million shs1.07 million shsPCRXPacira BioSciences$22.26-0.4%$25.42$15.92▼$27.64$1.00B0.4538,003 shs498,421 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AZYMEZymeworks$18.11+0.3%$15.27$9.03▼$18.49$1.36B1.51542,646 shs479,857 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPZMEpizyme0.00%0.00%0.00%0.00%0.00%IRWDIronwood Pharmaceuticals-6.62%0.00%+12.98%+115.43%-65.26%PCRXPacira BioSciences-0.40%-6.74%-17.92%-2.07%+37.24%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%ZYMEZymeworks+0.28%+8.57%+15.06%+40.61%+37.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPZMEpizyme$1.47$1.47$0.41▼$5.80$247.44M-0.413.23 million shs7,960 shsIRWDIronwood Pharmaceuticals$1.48-6.6%$1.26$0.53▼$5.13$257.46M0.31.39 million shs1.07 million shsPCRXPacira BioSciences$22.26-0.4%$25.42$15.92▼$27.64$1.00B0.4538,003 shs498,421 shsPRNBPrincipia Biopharma$100.05$100.05$25.35▼$101.89$3.32B0.86729,676 shsN/AZYMEZymeworks$18.11+0.3%$15.27$9.03▼$18.49$1.36B1.51542,646 shs479,857 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPZMEpizyme0.00%0.00%0.00%0.00%0.00%IRWDIronwood Pharmaceuticals-6.62%0.00%+12.98%+115.43%-65.26%PCRXPacira BioSciences-0.40%-6.74%-17.92%-2.07%+37.24%PRNBPrincipia Biopharma0.00%0.00%0.00%0.00%0.00%ZYMEZymeworks+0.28%+8.57%+15.06%+40.61%+37.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPZMEpizyme 0.00N/AN/AN/AIRWDIronwood Pharmaceuticals 2.25Hold$4.94233.78% UpsidePCRXPacira BioSciences 2.43Hold$33.4050.04% UpsidePRNBPrincipia Biopharma 0.00N/AN/AN/AZYMEZymeworks 2.91Moderate Buy$22.5024.24% UpsideCurrent Analyst Ratings BreakdownLatest ZYME, PRNB, PCRX, IRWD, and EPZM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025ZYMEZymeworksB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.0010/8/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)10/6/2025IRWDIronwood PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy9/27/2025IRWDIronwood PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/5/2025IRWDIronwood PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/14/2025PCRXPacira BioSciencesZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/11/2025ZYMEZymeworksCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$19.00 ➝ $22.007/25/2025PCRXPacira BioSciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$30.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPZMEpizyme$37.43M6.61N/AN/A($0.54) per share-2.72IRWDIronwood Pharmaceuticals$351.41M0.68$0.05 per share32.04($1.88) per share-0.79PCRXPacira BioSciences$700.97M1.43$4.30 per share5.18$16.86 per share1.32PRNBPrincipia Biopharma$35.16M94.50N/AN/A$10.95 per share9.14ZYMEZymeworks$122.87M11.08N/AN/A$6.63 per share2.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPZMEpizyme-$251.12M-$1.72N/AN/AN/A-391.90%-2,459.33%-69.74%N/AIRWDIronwood Pharmaceuticals$880K-$0.05N/A5.92N/A-2.25%-2.46%2.19%11/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A8.66N/A-18.08%13.29%6.61%11/5/2025 (Estimated)PRNBPrincipia Biopharma-$53.79M-$2.09N/AN/AN/AN/A-23.08%-21.11%N/AZYMEZymeworks-$118.67M-$0.97N/AN/AN/A-182.75%-23.00%-18.04%10/30/2025 (Estimated)Latest ZYME, PRNB, PCRX, IRWD, and EPZM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025IRWDIronwood Pharmaceuticals$0.08N/AN/AN/A$74.22 millionN/A11/5/2025Q3 2025PCRXPacira BioSciences$0.66N/AN/AN/A$182.86 millionN/A10/30/2025N/AZYMEZymeworks-$0.28N/AN/AN/AN/AN/A8/7/2025Q2 2025IRWDIronwood Pharmaceuticals-$0.02$0.14+$0.16$0.14$62.02 million$85.24 million8/7/2025N/AZYMEZymeworks-$0.52$0.03+$0.55N/A$17.18 million$48.73 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPZMEpizymeN/AN/AN/AN/AN/AIRWDIronwood PharmaceuticalsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/APRNBPrincipia BiopharmaN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPZMEpizymeN/A5.355.19IRWDIronwood PharmaceuticalsN/A0.820.82PCRXPacira BioSciences0.502.381.91PRNBPrincipia BiopharmaN/A17.0117.01ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPZMEpizyme76.45%IRWDIronwood PharmaceuticalsN/APCRXPacira BioSciences99.73%PRNBPrincipia Biopharma95.54%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipEPZMEpizyme23.40%IRWDIronwood Pharmaceuticals12.70%PCRXPacira BioSciences6.40%PRNBPrincipia Biopharma16.01%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPZMEpizyme250168.33 million128.97 millionOptionableIRWDIronwood Pharmaceuticals220162.43 million141.81 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionablePRNBPrincipia Biopharma6533.21 millionN/ANot OptionableZYMEZymeworks46075.17 million67.56 millionOptionableZYME, PRNB, PCRX, IRWD, and EPZM HeadlinesRecent News About These CompaniesZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ConferenceOctober 13 at 7:19 PM | tmcnet.comZymeworks Inc.: Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International ...October 13 at 7:19 PM | finanznachrichten.deZymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-⍺, at AACR-NCI-EORTC International ConferenceOctober 13 at 4:00 PM | globenewswire.comZymeworks (NYSE:ZYME) Stock Price Up 7.2% - Here's What HappenedOctober 11 at 11:45 AM | marketbeat.comEquities Analysts Set Expectations for Zymeworks Q3 EarningsOctober 11 at 2:19 AM | americanbankingnews.comLifesci Capital Forecasts Zymeworks' Q3 Earnings (NYSE:ZYME)October 10, 2025 | marketbeat.comZymeworks appoints Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | msn.comInMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of DirectorsOctober 9, 2025 | newsfilecorp.comNZymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development OfficerOctober 9, 2025 | globenewswire.comWhy Analysts See the Zymeworks Story Evolving After Key Pipeline and Market MovesOctober 8, 2025 | finance.yahoo.comQ1 Earnings Forecast for Zymeworks Issued By Lifesci CapitalOctober 8, 2025 | marketbeat.comPlatinum Investment Management Ltd. Decreases Stake in Zymeworks Inc. $ZYMEOctober 2, 2025 | marketbeat.comVoya Investment Management LLC Sells 43,861 Shares of Zymeworks Inc. $ZYMEOctober 1, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Given Average Recommendation of "Moderate Buy" by BrokeragesSeptember 29, 2025 | marketbeat.comBloom Burton Remains a Buy on Zymeworks (ZYME)September 21, 2025 | theglobeandmail.comRhumbline Advisers Sells 21,138 Shares of Zymeworks Inc. $ZYMESeptember 21, 2025 | marketbeat.comZymeworks Inc. $ZYME Shares Acquired by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLCSeptember 16, 2025 | marketbeat.comHealth Sector Innovations: From Blood Thinners to Bird Flu OutbreaksSeptember 3, 2025 | devdiscourse.comDZymeworks: Despite T-Cell Engager Setback, ADC Candidates Press OnSeptember 2, 2025 | seekingalpha.comZymeworks drops clinical-stage T-cell engager after assessing benefit-risk profileSeptember 2, 2025 | fiercebiotech.comFZymeworks halts development of cancer drug after trial setbackSeptember 2, 2025 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZYME, PRNB, PCRX, IRWD, and EPZM Company DescriptionsEpizyme NASDAQ:EPZMEpizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Ironwood Pharmaceuticals NASDAQ:IRWD$1.48 -0.11 (-6.62%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$1.54 +0.06 (+4.05%) As of 10/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.Pacira BioSciences NASDAQ:PCRX$22.26 -0.09 (-0.40%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$22.02 -0.24 (-1.06%) As of 10/13/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.Principia Biopharma NASDAQ:PRNBPrincipia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Zymeworks NYSE:ZYME$18.11 +0.05 (+0.28%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$18.04 -0.07 (-0.41%) As of 10/13/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
